Wockhardt trades jubilantly as its arm collaborates with Serum Life Sciences UK for manufacturing multiple vaccines in UK
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Wockhardt is currently trading at Rs. 319.85, up by 27.60 points or 9.44% from its previous closing of Rs. 292.25 on the BSE.
The scrip opened at Rs. 296.00 and has touched a high and low of Rs. 325.00 and Rs. 296.00 respectively. So far 157654 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 741.36 on 26-May-2021 and a 52 week low of Rs. 287.05 on 15-Mar-2022.
Last one week high and low of the scrip stood at Rs. 325.00 and Rs. 287.05 respectively. The current market cap of the company is Rs. 4573.91 crore.
The promoters holding in the company stood at 67.13%, while Institutions and Non-Institutions held 3.04% and 29.83% respectively.
Wockhardt’s subsidiary-- Wockhardt UK has entered into a collaboration agreement with Serum Life Sciences UK, a subsidiary of the Serum Institute of India, one of the world’s largest vaccine manufacturers to deliver a global vaccine programme.
This collaboration between a subsidiary of Wockhardt and Serum Life Sciences UK will help create considerable number of employment opportunities along with creation of new sterile fill and finish facility in Wrexham, North Wales (New Facility). A profit sharing arrangement has been made between the two parties for this New Facility that will deliver an additional 150 million vaccine doses of multiple vaccines. Wockhardt UK has manufactured a COVID-19 vaccine in collaboration with UK Government and AstraZeneca. Its collaboration with Serum Life Sciences is an addition to the earlier arrangement.
Wockhardt is a research based global pharmaceutical and Biotech Company headquartered in Mumbai, India.
